- 1	Substitute for for	m 1449A/PTO			COMPLETE IF KNOWN			
	INFORM	MATION 1	DISC	CLOSURE	Application Number	10/554,187		
	PETATEA	AENT DV	A DI		Filing Date	October 21, 2005		
/9	TP ESTATEM	IENI DI	API	PLICANI	First Named Inventor	Mark E. Duggan		
D	tr				Group Art Unit	1625		
135	(use as	many sheets	as ne	ecessary)	Examiner Name	B. M. Robinson		
13	43 Rept APR	1	of	2	Attorney Docket Number	21368YP		

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
		US 2003/0073687 A1		Vertex Pharmaceuticals, Inc.	04/17/2003		
					,		
	_						

			FOREIC	GN PATENT	T DOCUMENTS	
	Cite No.		Foreign Patent Document	l .		Date of Publication of
Examiner Initials*		· ·		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		PCT	WO 03/011854 A1	_	Vertex Pharmaceuticals, Inc.	02/13/2003
		PCT	WO 02/083064 A2		Merck & Co., Inc.	10/24/2002

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Su	bstitute for form 1449B/PTO			COMPLETE IF KNOWN			
	NFORMATION 1	DIS	CLOSURE	Application Number	10/554,187		
6	TATEMENT DV	A TO		Filing Date	October 21, 2005		
3	TATEMENT BY	Ar	PLICANI	First Named Inventor	Mark E. Duggan		
			,	Group Art Unit	1625		
	(use as many sheets	as n	ecessary)	Examiner Name	B. M. Robinson		
Sheet	2	of	2	Attorney Docket Number	21368YP		

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.				
	:					
	,					
<u> </u>						

Examiner Signature	Date Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.